

Supplementary Table 1.

Regression models predicting cognitive skills and dementia symptoms at baseline/change in cognition and dementia symptoms with amyloid age.

	mCRT total score			mCRT intrusions			DSMSE			NTG-EDSD		
	B	95% CI	p	B	95% CI	p	B	95% CI	p	B	95% CI	p
Amyloid age	-0.49	-0.60, -0.38	< 0.01	0.41	0.32, 0.51	< 0.01	-0.61	-0.81, -0.41	<0.01	0.38	0.26, 0.50	< 0.01
Amyloid age ²	-0.04	-0.05, -0.03	< 0.01	0.03	0.02, 0.04	< 0.01	-0.03	-0.05, -0.01	<0.01	0.02	0.01, 0.03	< 0.01
Sex (female)	1.01	-0.61, 2.63	0.22	-1.11	-2.49, 0.28	0.12	3.02	0.16, 5.89	0.04	0.20	-1.51, 1.91	0.82
Lifetime ID level (vs. Mild)												
Moderate	-1.32	-3.11, 0.48	0.15	-0.04	-1.57, 1.50	0.96	-8.99	-12.19, -5.80	< 0.01	1.21	-0.69, 3.12	0.22
Severe/Profound	-6.27	-8.74, -3.79	< 0.01	3.62	1.50, 5.75	< 0.01	-23.76	-28.08, -19.45	< 0.01	1.22	-1.36, 3.80	0.35
APOE e4	0.99	-0.95, 2.94	0.32	-0.10	-1.77, 1.58	0.91	0.11	-3.33, 3.56	0.95	-0.60	-2.67, 1.47	0.57
	Δ mCRT total score			Δ mCRT intrusions			Δ DSMSE			Δ NTG-EDSD		
Amyloid age	-0.41	-0.60, -0.22	< 0.01	0.29	0.02, 0.55	0.03	-0.47	-0.77, -0.18	< 0.01	0.25	0.02, 0.48	0.03
Amyloid age ²	-0.03	-0.05, -0.01	< 0.01	-0.01	-0.03, 0.02	0.51	-0.04	-0.07, -0.01	0.01	0.04	0.01, 0.06	< 0.01
Amyloid age ³				-0.002	-0.01, -3.25x10 ⁻⁴	0.02						
Sex (female)				-0.42	-2.52, 1.69	0.70						
Lifetime ID level (vs. Mild)	1.06	-1.23, 3.34	0.36				1.22	-2.38, 4.82	0.50	-0.22	-2.97, 2.53	0.88
Moderate	-0.01	-2.67, 2.66	0.99	0.17	-2.27, 2.61	0.89	-0.61	-4.80, 3.58	0.77	0.93	-2.25, 4.12	0.56
Severe/Profound	0.30	-2.70, 3.30	0.84	-0.18	-2.92, 2.57	0.90	1.19	-3.53, 5.92	0.62	-0.14	-3.83, 3.55	0.94
APOE e4	1.21	-1.45, 3.87	0.37	-0.64	-3.07, 1.78	0.60	2.40	-1.78, 6.58	0.26	-0.91	-4.10, 2.28	0.57

mCRT = Modified Cued Recall Test; DSMSE = Down Syndrome Mental Status Examination; NTG-EDSD = National Task Group-Early Detection Screen for Dementia; ID = Intellectual disability; APOE = Apolipoprotein E


Supplementary Table 2.

Regression models predicting tau PET SUVR in Braak NFT regions I-II, III-IV, V-VI with amyloid age. Δ = change in Braak NFT

	Braak NFT regions I-II			Braak NFT regions III-IV			Braak NFT regions V-VI		
	B	95% CI	p	B	95% CI	p	B	95% CI	p
Amyloid age	0.02	0.01, 0.02	< 0.01	0.01	0.01, 0.02	<0.01	<0.01	- <0.01, 0.01	0.09
Amyloid age ²	0.01	<0.01, 0.01	<0.01	<0.01	<0.01, <0.01	<0.01	<0.01	<0.01, <0.01	<0.01
Amyloid age ³				<0.01	<0.01, <0.01	<0.01	<0.01	<0.01, <0.01	<0.01
Sex (female)	-0.01	-0.04, 0.04	0.97	-0.01	-0.04, 0.03	0.78	- 0.01	-0.04, 0.03	0.78
Lifetime ID level (vs. Mild)									
Moderate	0.03	-0.02, 0.07	0.21	<0.01	-0.03, 0.04	0.87	-0.02	-0.06, 0.02	0.29
Severe/Profound	-0.01	-0.07, 0.05	0.69	-0.01	-0.06, 0.04	0.58	- <0.01	-0.06, 0.05	0.94
APOE e4	0.02	-0.03, 0.07	0.48	-0.01	-0.05, 0.03	0.79	- <0.01	-0.05, 0.04	0.90
		Δ Braak NFT regions I-II			Δ Braak NFT regions III-IV			Δ Braak NFT regions V-VI	
Amyloid age	0.01	0.01, 0.02	<0.01	0.01	0.01, 0.02	<0.01	0.01	0.01, 0.02	<0.01
Amyloid age ²	<0.01	-<0.01, <0.01	0.86	<0.01	<0.01, <0.01	0.01	<0.01	<0.01, <0.01	0.01
Amyloid age ³	<0.01	-<0.01, -<0.01	<0.01	-<0.01	-<0.01, -<0.01	0.01	-<0.01	-<0.01, -<0.01	0.03
Sex (female)	-0.01	-0.04, 0.03	0.68	-<0.01	-0.04, 0.03	0.87	-<0.01	-0.05, 0.04	0.88
Lifetime ID level (vs. Mild)									
Moderate	<0.01	-0.04, 0.04	0.85	0.03	-0.02, 0.07	0.27	0.02	-0.03, 0.07	0.50
Severe/Profound	0.01	-0.04, 0.05	0.67	<0.01	-0.05, 0.05	0.95	-0.01	-0.06, 0.05	0.81
APOE e4	0.01	-0.03, 0.05	0.75	-0.01	-0.05, 0.04	0.78	-0.01	-0.06, 0.04	0.68

ID = Intellectual disability; APOE = Apolipoprotein E

Supplementary Figure 1. ANOVA comparison between amyloid age categorized by clinical status (cognitively stable, MCI, AD, unable to determine). Amyloid age of 0 years indicates A β + (18 CL).



Supplementary Figure 2. ANOVA comparisons between tau Braak NFT SUVR (NFT I.II; NFT III.IV; NFT V.VI) categorized by clinical status (cognitively stable, MCI, AD, unable to determine).

